Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 261

Results For "improve"

2611 News Found

Piramal Enterprises cashing in on opportunities: ICICI Securities
News | March 02, 2021

Piramal Enterprises cashing in on opportunities: ICICI Securities

PEL will explore the PLI scheme and apply if its beneficial.


Pharma stalwarts demystify COVID-19 impact on industry
News | March 01, 2021

Pharma stalwarts demystify COVID-19 impact on industry

Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.


India approves PLI scheme for pharmaceuticals
News | February 26, 2021

India approves PLI scheme for pharmaceuticals

Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies


2021 will be a game-changer for pharma industry, says experts
News | February 13, 2021

2021 will be a game-changer for pharma industry, says experts

The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse


LupinLife Launches ayurvedic energy supplement
News | February 12, 2021

LupinLife Launches ayurvedic energy supplement

Be One is a 100% Ayurvedic health and wellness supplement.


Laurus Q3 FY21 revenue up 76%; PAT grows 274%
News | January 29, 2021

Laurus Q3 FY21 revenue up 76%; PAT grows 274%

The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.


Lonza reports 12% sales growth in 2020
News | January 28, 2021

Lonza reports 12% sales growth in 2020

Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.


Slow recovery in biosimilars for Biocon: ICICI Securities
News | January 26, 2021

Slow recovery in biosimilars for Biocon: ICICI Securities

Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.